ScottJDiedeMDPhD

Pediatric Hematology & Oncology • North Wales, PA

Executive Director, Late Melanoma Global Development Lead, Merck Research Laboratories

Join to view full profile

Dr. Diede is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Diede's full profile

Already have an account?

Office
351 N Sumneytown Pike
Stop UG4D-72
North Wales, PA 19454
Phone+1 267-305-5994

Fax+1 267-305-6537

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of WashingtonResidency, Pediatrics, 2004 - 2005
University of WashingtonInternship, Pediatrics, 2003 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003
University of ChicagoPhD, Pathology, 2001
University of ChicagoBA, Chemistry, 1988 - 1992

Certifications & Licensure

PA State Medical License 2014 - 2016
WA State Medical License 2005 - 2015

Awards, Honors, & Recognition

Young Investigator Award Alex's Lemonade Stand for Childhood Cancer Research, 2010
Scholar St. Baldrick's Foundation, 2010
Basic Research Fellowship in memory of Emily Ann Dorfman American Brain Tumor Association, 2010
Scholar Hyundai Hope on Wheels, 2010
Young Investigator Award American Society of Clinical Oncology, 2008
Scholar Child Health Research Center, UWSOM, 2008
Special Alternative Pathway in Pediatric Hematology-Oncology American Board of Pediatrics, 2005
Alpha Omega Alpha The University of Chicago Pritzker School of Medicine, 2003
Medical Scientists Training Program The Univeristy of Chicago Pritzker School of Medicine, 1992
Join now to see all

Clinical Trials

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) Start of enrollment: 2011 Mar 04
Completed
Phase 1
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) Start of enrollment: 2012 Nov 20
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) Start of enrollment: 2013 Aug 28
Completed
Phase 3
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Start of enrollment: 2014 May 29
Completed
Phase 1, Phase 2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) Start of enrollment: 2014 Jul 15
Completed
Phase 1
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma Start of enrollment: 2014 Dec 08
Terminated
Phase 3
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Start of enrollment: 2015 Mar 18
Recruiting
Phase 1, Phase 2
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) Start of enrollment: 2015 Jul 16
Active, not recruiting
Phase 3
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) Start of enrollment: 2016 Jun 21
Completed
Phase 3
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) Start of enrollment: 2016 Jul 08
Completed
Phase 1
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment Start of enrollment: 2017 Oct 03
Active, not recruiting
Phase 2
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Start of enrollment: 2018 Jun 28
Terminated
Phase 2
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 3
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) Start of enrollment: 2018 Nov 19
Completed
Phase 1
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Start of enrollment: 2019 Jan 31
Active, not recruiting
Phase 4
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Start of enrollment: 2019 Jan 30
Completed
Phase 2
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Start of enrollment: 2019 Mar 12
Active, not recruiting
Phase 3
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Recruiting
Phase 2
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) Start of enrollment: 2020 Jun 26
Active, not recruiting
Phase 1, Phase 2
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) Start of enrollment: 2020 Jun 26
Active, not recruiting
Phase 1, Phase 2
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) Start of enrollment: 2020 Jul 01
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

15 citations
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, Matteo S. Carlino, Tara C. Mitchell
European Journal of Cancer. 2021-11-01
471 citations
Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (...
Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari M. Vanderwalde, Robert H.I. Andtbacka
Cell. 2018-08-09
58 citations
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber
European Journal of Cancer. 2021-02-01